127 related articles for article (PubMed ID: 6707701)
1. Practical considerations for the establishment of a screening procedure for the assessment of biological response modifiers.
Talmadge JE; Oldham RK; Fidler IJ
J Biol Response Mod; 1984; 3(1):88-109. PubMed ID: 6707701
[TBL] [Abstract][Full Text] [Related]
2. The NCI preclinical screen of biological response modifiers.
Talmadge JE; Fidler IJ; Oldham RK
Behring Inst Mitt; 1984 May; (74):189-94. PubMed ID: 6206841
[TBL] [Abstract][Full Text] [Related]
3. The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers.
Talmadge JE; Herberman RB
Cancer Treat Rep; 1986 Jan; 70(1):171-82. PubMed ID: 3510733
[No Abstract] [Full Text] [Related]
4. Biological Response Modifiers Programme and cancer chemotherapy.
Oldham RK
Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193
[TBL] [Abstract][Full Text] [Related]
5. Tumor models to investigate the therapeutic efficiency of immunomodulators.
Talmadge E; Lenz BF; Collins MS; Uithoven KA; Schneider MA; Adams JS; Pearson JW; Agee WJ; Fox RE; Oldham RK
Behring Inst Mitt; 1984 May; (74):219-29. PubMed ID: 6477354
[TBL] [Abstract][Full Text] [Related]
6. Design of clinical trials with biological response modifiers.
Herberman RB
Cancer Treat Rep; 1985 Oct; 69(10):1161-4. PubMed ID: 2412692
[TBL] [Abstract][Full Text] [Related]
7. Biological response modifiers for the therapy of cancer.
Herberman RB
Ann Allergy; 1985 May; 54(5):376-80. PubMed ID: 3994067
[TBL] [Abstract][Full Text] [Related]
8. Assessment of biological responses: what to measure and when.
Maluish AE; Herberman RB
Cancer Treat Rep; 1985 Oct; 69(10):1165-9. PubMed ID: 3899356
[TBL] [Abstract][Full Text] [Related]
9. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
10. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells].
Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L
Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759
[TBL] [Abstract][Full Text] [Related]
11. Use of activated natural killer cells for tumor immunotherapy in mouse and human.
Basse PH; Whiteside TL; Herberman RB
Methods Mol Biol; 2000; 121():81-94. PubMed ID: 10818719
[No Abstract] [Full Text] [Related]
12. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
Tahara H; Lotze MT
Gene Ther; 1995 Mar; 2(2):96-106. PubMed ID: 7719935
[TBL] [Abstract][Full Text] [Related]
13. Preclinical approaches to the development of effective immunotherapeutic protocols for the treatment of metastasis.
Talmadge JE
Prog Clin Biol Res; 1986; 212():197-215. PubMed ID: 3520577
[No Abstract] [Full Text] [Related]
14. Natural killer cell-based immunotherapy in cancer: current insights and future prospects.
Sutlu T; Alici E
J Intern Med; 2009 Aug; 266(2):154-81. PubMed ID: 19614820
[TBL] [Abstract][Full Text] [Related]
15. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
Fujii S
Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
[TBL] [Abstract][Full Text] [Related]
16. Immune monitoring of cancer patients undergoing experimental immunotherapy.
Shankar G; Salgaller ML
Curr Opin Mol Ther; 2000 Feb; 2(1):66-73. PubMed ID: 11249653
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases.
Gately MK; Gubler U; Brunda MJ; Nadeau RR; Anderson TD; Lipman JM; Sarmiento U
Ther Immunol; 1994 Jun; 1(3):187-96. PubMed ID: 7584494
[TBL] [Abstract][Full Text] [Related]
18. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
Lin CY; Chuang TF; Liao KW; Huang YJ; Pai CC; Chu RM
Cancer Lett; 2008 Dec; 272(2):285-95. PubMed ID: 18760876
[TBL] [Abstract][Full Text] [Related]
19. Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections.
Terunuma H; Deng X; Dewan Z; Fujimoto S; Yamamoto N
Int Rev Immunol; 2008; 27(3):93-110. PubMed ID: 18437601
[TBL] [Abstract][Full Text] [Related]
20. Bio-immunotherapy for cancer in experimental studies and clinical application: current status and future challenges.
Shen RN; Lu L; Kaiser HE; Broxmeyer HE
In Vivo; 1994; 8(5):643-52. PubMed ID: 7727711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
